Moderna (MRNA) Other Accumulated Expenses (2017 - 2026)

Moderna has reported Other Accumulated Expenses for 10 years, with the latest figure at $163.0 million in Q2 2026.

• Other Accumulated Expenses for Q2 2026 came in at $163.0 million, down 15.1% year-over-year; the trailing twelve-month figure through Jun 2026 was $163.0 million (down 15.1% YoY), and the FY2025 annual result was $185.0 million, down 16.29% from the prior year.
• Other Accumulated Expenses fell to $163.0 million in Q2 2026, from $220.0 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $553.0 million in Q3 2022 and troughed at $42.0 million in Q2 2024.
• A 5-year average of $215.2 million and a median of $216.0 million in 2023 frame the typical range for Other Accumulated Expenses.
• The widest annual swing landed in 2024, when Other Accumulated Expenses plunged 82.2%; it then surged 357.14% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $249.0 million in 2022, then plunged by 48.19% to $129.0 million in 2023, then surged by 71.32% to $221.0 million in 2024, then decreased by 16.29% to $185.0 million in 2025, then retreated by 11.89% to $163.0 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $163.0 million in Q2 2026, $220.0 million in Q1 2026, and $185.0 million in Q4 2025.